IMMUTEP LTD/S (NASDAQ:IMMP) Rating Increased to Buy at ValuEngine

ValuEngine upgraded shares of IMMUTEP LTD/S (NASDAQ:IMMP) from a hold rating to a buy rating in a research note published on Thursday, ValuEngine reports.

Separately, Maxim Group reiterated a buy rating and set a $7.00 price objective on shares of IMMUTEP LTD/S in a research note on Wednesday, May 1st.

Shares of NASDAQ:IMMP traded down $0.03 during midday trading on Thursday, reaching $1.49. 12,774 shares of the company traded hands, compared to its average volume of 30,446. IMMUTEP LTD/S has a 12 month low of $1.48 and a 12 month high of $4.21. The company has a market capitalization of $51.51 million, a price-to-earnings ratio of -3.91 and a beta of 1.45. The business’s fifty day moving average price is $1.73.

A hedge fund recently raised its stake in IMMUTEP LTD/S stock. Deutsche Bank AG lifted its stake in shares of IMMUTEP LTD/S (NASDAQ:IMMP) by 23.1% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 100,040 shares of the biotechnology company’s stock after purchasing an additional 18,800 shares during the quarter. Deutsche Bank AG owned 0.37% of IMMUTEP LTD/S worth $184,000 as of its most recent SEC filing. Institutional investors and hedge funds own 2.15% of the company’s stock.


Immutep Limited, a biotechnology company, engages in the research, development, and commercialization of biological products. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its therapeutics are based on the lymphocyte activation gene-3 (LAG-3) Ig fusion protein, a cell surface molecule that plays a role in regulating T cells.

Recommended Story: What is a Reverse Stock Split?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for IMMUTEP LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMMUTEP LTD/S and related companies with's FREE daily email newsletter.